Literature DB >> 29081188

[Cytogenetic abnormalities and prognosis of 532 patients with multiple myeloma].

H Wu1, H Zhang, H Y He, H Jiang, Y Y Zhao, R An, J He, R Li, J Lu, J Hou.   

Abstract

Objective: To explore the effect of 6 common cytogenetic abnormalities on the prognosis of multiple myeloma (MM).
Methods: Myeloma cells from a cohort of 532 newly-diagnosed MM patients enrolled were enriched by CD138 immunomagnetic beads, then detected 13q-, 17p-, 1q+, t (4;14), t (11;14) and t (14;16) and other common genetic abnormalities in MM by using interphase fluorescence in situ hybridization (FISH) technique to compare the influence of different genetic abnormalities on their prognoses.
Results: The rate of cytogenetic abnormalities was 78.20% (416/532) in 532 patients, of which 13q-accounted for 42.29% (225/532), 17p-16.35% (87/532), 1q+ 53.38% (284/532), t (4;14) 25.94% (138/532), t (11;14) 21.62% (115/532), t (14;16) 2.07% (11/532). Six kinds of cytogenetic abnormalities were analyzed, 13q- and 17p-, 1q+, t (4; 14), t (14;16) were all correlated (P <0.05). The univariate analysis indicated that 13q-, 1q+, t (4;14) and t (14;16) had a significant effect on progression-free survival (PFS), 13q-, 17p-, t (4;14) and t (14;16) had a marked influence on overall survival (OS). The multivariate analysis showed that 1q+, t (4;14) and t (14;16) were independent adverse factors of PFS, 17p-, t (4;14) and t (14;16) were independent unfavorable factors of OS. According to the independent prognosis factors number-based groups, the median PFS with 0, 1, 2, 3 independent prognosis factors of patients were 30.9, 28.4, 18.7 and 17.6 months (P =0.035) respectively, and the median OS were 54.4, 46.1, 38.0 and 21.2 months (P =0.004) respectively.
Conclusion: 1q+, 17p-, t (4;14) and t (14;16) were independent prognostic factors affecting the survival of MM patients. 13q-is often accompanied by 17p-, 1q + and (or) t (4;14) , simply 13q- was not an independent prognostic factor; the more number of independent prognostic factors, the worse the prognosis of patients.

Entities:  

Keywords:  Cytogenetics; Fluorescence in situ hybridization; Multiple, myeloma; Prognosis

Mesh:

Year:  2017        PMID: 29081188     DOI: 10.3760/cma.j.issn.0253-2727.2017.09.002

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  6 in total

1.  [The correlations and prognostic value of neutrophil to lymphocyte ratio, immunophenotype and cytogenetic abnormalities in patients with newly diagnosed multiple myeloma].

Authors:  J J Hu; S M Nie; Y Gao; X S Yan; J X Huang; T L Li; S S Liu; C X Mao; J J Zhou; Y J Xu; W Wang; F J Meng; X Q Feng
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-12-14

2.  [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].

Authors:  X L Liu; Y P Yang; J Bai; T T Yue; P Y Yang; Y Zhang; H Q Fan; W Li; F Y Jin
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-11-14

3.  [Epidemiological analysis of cytogenetic abnormalities in patients with newly-diagnosed multiple myeloma: a multi-center retrospective study].

Authors:  R F Yuan; Y J Dong; C R Li; W R Huang; L M Zhang; Q Zhu; L Xu; Y J Xu; Q Xu; G X Gao; F Y Jin
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

4.  [Efficacy and safety analysis of BCL-2 inhibitor in relapsed/refractory multiple myeloma with t (11;14) in a single center].

Authors:  J Y Bi; L Wen; W B Duan; Y Liu; S S Wang; X J Huang; J Lu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-02-14

Review 5.  Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma.

Authors:  Hamid Ehsan; Ahsan Wahab; Zunairah Shah; Muhammad Khawar Sana; Adeel Masood; Abdul Rafae; Hamza Hashmi
Journal:  J Hematol       Date:  2021-06-16

6.  [Prognostic analysis of 182 newly diagnosed multiple myeloma patients with high risk cytogenetic abnormalities].

Authors:  X L Liu; J Bai; H Q Fan; Y P Yang; T T Yue; Y Zhang; P Y Yang; S J Gao; W Li; F Y Jin
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-08-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.